This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Letter to the Editor: Ms Robinson and colleagues recently summarized data from the Active Bacterial Core Surveillance/Emerging Infections Program Network to understand the epidemiology of Streptococcus pneumoniae in invasive pneumococcal disease (IPD).¹ The authors state, "We sought to estimate the expected effect of the recently licensed vaccine [7-valent pneumococcal conjugate vaccine] . . . " and, "More than half of these cases [IPD] occurred in adults who had an indication for pneumococcal polysaccharide vaccination . . . " However, it is important to note that the "expected effect" and actual effectiveness of pneumococcal vaccination may differ markedly.

While the pneumococcal polysaccharide vaccine (PPV) is 50% to 80% effective in reducing serotype-specific IPD,² it does not provide 100% protection against vaccine serotypes. Incomplete protection may be due to an inadequate response to all vaccine serotypes,³ poor response in patients most prone to pneumococcal infection,² or lack of an amnestic response. Furthermore, . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Epidemiology of Invasive Streptococcus pneumoniae Infections in the United States, 1995-1998: Opportunities for Prevention in the Conjugate Vaccine Era
Katherine A. Robinson, Wendy Baughman, Gretchen Rothrock, Nancy L. Barrett, Margaret Pass, Catherine Lexau, Barbara Damaske, Karen Stefonek, Brenda Barnes, Jan Patterson, Elizabeth R. Zell, Anne Schuchat, Cynthia G. Whitney, and for the Active Bacterial Core Surveillance /Emerging Infections Program Network
JAMA. 2001;285(13):1729-1735.
ABSTRACT | FULL TEXT